Genaphora

Genaphora

Genaphora, has now developed groundbreaking, real time, quantitative PCR (qPCR) and endpoint PCR diagnostics kits. Our proprietary computational biology and chimeric DNA/RNA primer and probes technology for increased sensitivity and specificity have been tested and patented. Genaphora’s assays provide unprecedented sensitivity – down to single copy detection. We are now launching our AquatiQPCR© line of qPCR assays for the detection of waterborne pathogens.

Company details

4 Habarzel st. , Tel-Aviv , 69710 Israel

Locations Served

Business Type:
Manufacturer
Industry Type:
Environmental
Market Focus:
Internationally (various countries)

Founded in 2008, Genaphora is introducing a breakthrough in endpoint and real time qPCR diagnostics.

Genaphora is leveraging existing PCR technology

PCR (Polymerase Chain Reaction) is a method for exponential amplification of specific DNA strands. .qPCR, or real-time PCR, is a method used  to quantify the amplified segment in real time. In PCR, nonspecific byproduct appears rather frequently and reduces the efficiency and sensitivity of the amplification reaction. Our technology is inherently designed to overcome this problem.

Computational-biology platform

Genaphora developed its own computational biology platform employing thermodynamics calculation and modifications of linguistic complexity. This unique approach ensures the best fit primers and probes out of a whole genome sequence of any given organism. The result of which is a higher sensitivity and specificity.

Chimeric DNA/RNA primers and probes for higher sensitivity and specificity

Genaphora scientists have developed a platform technology (patents registered in the USA and China) providing a generic approach to the design of novel DNA/RNA primers and probes for any organism of interest. During DNA amplification, target sequences are specifically amplified, while primer dimers and other nonspecific sequences are eliminated. This results in a highly sensitive assay down to single cell.

Development of water testing assays

Genaphora has established a strategic partnership with Mekorot, Israel’s National Water Company, and received support from the Israeli Office of the Chief Scientist. This successful collaboration resulted in the development of qPCR-based assays for the detection of waterborne pathogens and indicators (Cryptosporidium,Giardia andE. coli).

Genaphora has completed the development of AquatiQPCR©– C/G, a multiplex assay for detection ofCryptosporidium andGiardia in water (source and treated) and introducing it to the water testing industry.

Genaphora is poised to become a significant player in the fast growing market of molecular diagnostics by introducing innovative, computational-biology-derived products and solutions to emerging markets worldwide.